Phathom Pharmaceuticals, Inc. (PHAT) Tops Q3 EPS by 15c

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q3 EPS of ($1.32), $0.15 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $16.4 million versus the consensus estimate of $12.61 million.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Kingsoft Cloud Holdings Limited (KC) 2200 contracts of August 10 puts trade
• ZoomInfo (GTM) 27K contracts of October 2 weekly 3 puts trade share price up 3.8%